Novocure Reports First Quarter 2019 Financial Results and Provides Company Update
Quarterly net revenues of $73.3 million, representing 41 percent growth versus the first quarter 2018 and 5 percent growth versus the fourth quarter 2018 Mesothelioma humanitarian device exemption application under FDA review Enrollment ongoing in four phase 3 pivotal trials, creating a significant market expansion opportunity in some of the most aggressive forms of cancer …